Helixmith Participates in the 17th Bio Korea 2022

[Asia Economy Reporter Jang Hyowon] Helixmith announced on the 10th that it will participate in the ‘17th Bio Korea 2022,’ which will be held for three days starting from the 11th. At this event, the company plans to seek partnerships based on the excellence and distinctiveness of its CGT Plant (Cell & Gene Therapy Plant), a GMP production facility for cell and gene therapy products.

Bio Korea, hosted by the Korea Health Industry Development Institute, is the largest bio industry event in Korea, now in its 17th year. Executives, consulting experts, researchers, policy makers, and investors from the global biohealth sector participate to share insights on the global biohealth industry landscape and technology development trends.

At this event, Helixmith will introduce the CGT Plant (Cell & Gene Therapy Plant) to bio-pharmaceutical development companies aiming to develop cell and gene therapy products. In September last year, Helixmith established the CGT Plant, a cell and gene therapy production facility, at its headquarters in Magok, Seoul.

Through the CGT Plant, Helixmith rapidly manufactures cell and gene therapy products desired by companies and provides high-quality clinical samples at a global standard by thoroughly analyzing the produced pharmaceuticals to ensure quality. The most significant feature of the CGT Plant is that it offers comprehensive solutions across all areas, including manufacturing itself, provision of proprietary vectors, process development, and analytical technology development. By simply providing the nucleotide sequence to the CGT Plant, companies can receive a one-stop service to produce CAR-T products and enter clinical trials.

Seungshin Yoo, CEO of Helixmith, stated, “As domestic and international demand for new drug development continues to rise, the cell and gene therapy CDMO business is expected to gain more attention. At this event, we will actively introduce the differentiated technologies and one-stop services of the CGT Plant for cell and gene therapy product development and production.”

He added, “We aim to address the diverse needs of bio ventures and play a significant role in strengthening the international competitiveness of Korea’s advanced biopharmaceutical companies.”

This content was produced with the assistance of AI translation services.